title: Implantable cardioverter defibrillators: arrhythmias. A rapid and systematic review.
abstract: PROPOSED SERVICE: The service proposed is the use of implantable cardioverter defibrillators (ICDs) in the management of risk factors leading to sudden cardiac death (SCD). ICDs are similar in size to a pacemaker and are intended to prevent death due to life-threatening ventricular tachyarrhythmias.
  SCD occurs in approximately 100,000 people annually in the UK and is usually due to ventricular tachyarrhythmia. Increasing numbers of people are surviving a first episode of ventricular tachyarrhythmia and are at high risk of further episodes. Standard treatments for those at high risk have been anti-arrhythmic drugs, catheter ablation or surgery and, increasingly, vasodilating beta-blockers.
  
  
  METHODS
  Electronic databases were searched for the period 1980-99. In addition, bibliographies of related papers were assessed for relevant studies, and experts were contacted to identify additional published and unpublished references. Studies were included if they were systematic reviews, meta-analyses or randomised controlled trials (RCTs) comparing ICDs with conventional therapy in people at high risk of SCD.
  Seven RCTs on effectiveness the majority of which were of good quality, eight cost-effectiveness analyses most of which were older studies and based on non-UK data, and two good-quality literature reviews one of which was a critical appraisal of the literature of effectiveness and cost-effectiveness of ICD therapy, and the other a review of the cost-effectiveness of ICD therapy. These showed changes in absolute risk of total mortality ranging from an increase of 1.7% to a reduction of 22.8% (relative risk reductions of -7% to +54%).
  Estimated benefits from RCT data are 0.23-0.8 additional years of life with ICD therapy compared with anti-arrhythmic drug therapy.
  
  
  RESULTS
  Unit cost of ICDs (based on 1999/2000 prices), ranges from pound 12,500 to pound 22,000. Total discounted costs for 3 years range from pound 20,000 to pound 29,000. COST-EFFECTIVENESS: Cost-effectiveness estimates in the literature identified range from $11,000 to $146,000 per life-year saved. Using UK cost data from three hospitals and trial survival data from one RCT, the estimate of cost-effectiveness from this review ranges between pound 20,250 and pound 87,000 per life-year saved. COST-UTILITY: Cost per quality-adjusted life-year is estimated by the authors of this review at pound 21,300 to pound 108,800 (using survival data from one trial and quality-of-life indices derived from clinical opinion). These figures remain speculative until quality-of-life data from ongoing trials are available to inform future UK cost-effectiveness/utility analyses.
  
  
  CONCLUSIONS
  If implemented for indications supported by evidence from RCTs, ICDs may cost the NHS in excess of pound 24 million per annum.
  
  
  CONCLUSIONS
  Future research should include the use of British Pacing and Electrophysiological Group registries to assess the use of different types of ICD and current service provision.
authors.affiliation: University of Southampton, Southampton, UK.
authors.forename: J
authors.initials: J
authors.lastname: Parkes
authors.forename: J
authors.initials: J
authors.lastname: Bryant
authors.forename: R
authors.initials: R
authors.lastname: Milne
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D019057:Quality-Adjusted Life Years; D012307:Risk Factors; D017180:Tachycardia, Ventricular / Q000517:prevention & control*
chemical_list: D000889:Anti-Arrhythmia Agents